Literature DB >> 15147148

Prohepcidin accumulates in renal insufficiency.

Youri E C Taes1, Birgitte Wuyts, Johan R Boelaert, An S De Vriese, Joris R Delanghe.   

Abstract

BACKGROUND: The understanding of iron metabolism has increased substantially during the last decade. Several new transporters and iron regulating molecules have been described. Hepcidin, a small hepatic peptide has recently been proposed as a central mediator of dietary iron absorption. We have investigated the relationship between prohepcidin, the prohormone of hepcidin, and renal function and iron status.
METHODS: Forty six patients, referred for 51Cr-EDTA clearance were included in this study. Renal function was assessed by determination of serum creatinine, creatinine clearance, serum cystatin C and serum beta-trace protein. Iron status was evaluated by determination of serum iron, transferrin, transferrin saturation and serum ferritin. All determinations were performed using commercial reagents (Roche Diagnostics, Dade Behring). Serum prohepcidin was determined using an ELISA kit.
RESULTS: Serum prohepcidin was found to correlate with 51Cr-EDTA clearance (r = -0.44; p = 0.005), creatinine clearance, serum creatinine, beta-trace protein and cystatin C. No significant relationship was observed between serum prohepcidin concentrations and red cell count, hemoglobin concentration or hematocrit. No significant correlation was found in this population between prohepcidin concentrations and iron status.
CONCLUSION: Increased serum prohepcidin concentrations were observed with declining kidney function. We observed no relationship between red cell indices or iron status and serum prohepcidin concentrations.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15147148     DOI: 10.1515/CCLM.2004.069

Source DB:  PubMed          Journal:  Clin Chem Lab Med        ISSN: 1434-6621            Impact factor:   3.694


  16 in total

1.  Urinary hepcidin-25 and risk of acute kidney injury following cardiopulmonary bypass.

Authors:  Julie Ho; Martina Reslerova; Brent Gali; Ang Gao; Jennifer Bestland; David N Rush; Peter W Nickerson; Claudio Rigatto
Journal:  Clin J Am Soc Nephrol       Date:  2011-09-01       Impact factor: 8.237

2.  Synthetic hepcidin causes rapid dose-dependent hypoferremia and is concentrated in ferroportin-containing organs.

Authors:  Seth Rivera; Elizabeta Nemeth; Victoria Gabayan; Miguel A Lopez; Dina Farshidi; Tomas Ganz
Journal:  Blood       Date:  2005-06-02       Impact factor: 22.113

3.  Mammalian target of rapamycin (mTOR) inhibitors: potential uses and a review of haematological adverse effects.

Authors:  Sofia Sofroniadou; David Goldsmith
Journal:  Drug Saf       Date:  2011-02-01       Impact factor: 5.606

4.  Hepcidin-25 concentrations are markedly increased in patients with chronic kidney disease and are inversely correlated with estimated glomerular filtration rates.

Authors:  Jason S Troutt; Anthony M Butterfield; Robert J Konrad
Journal:  J Clin Lab Anal       Date:  2013-11       Impact factor: 2.352

5.  Serum pro-hepcidin levels in rheumatoid arthritis and systemic lupus erythematosus.

Authors:  Suleyman Serdar Koca; Ahmet Isik; Bilal Ustundag; Kerem Metin; Kader Aksoy
Journal:  Inflammation       Date:  2008-02-16       Impact factor: 4.092

6.  Hepcidin--a potential novel biomarker for iron status in chronic kidney disease.

Authors:  Joshua Zaritsky; Brian Young; He-Jing Wang; Mark Westerman; Gordana Olbina; Elizabeta Nemeth; Tomas Ganz; Seth Rivera; Allen R Nissenson; Isidro B Salusky
Journal:  Clin J Am Soc Nephrol       Date:  2009-04-30       Impact factor: 8.237

7.  A novel immunological assay for hepcidin quantification in human serum.

Authors:  Vasiliki Koliaraki; Martha Marinou; Theodoros P Vassilakopoulos; Eustathios Vavourakis; Emmanuel Tsochatzis; Gerassimos A Pangalis; George Papatheodoridis; Alexandra Stamoulakatou; Dorine W Swinkels; George Papanikolaou; Avgi Mamalaki
Journal:  PLoS One       Date:  2009-02-24       Impact factor: 3.240

8.  Inflammation and its impact on anaemia in chronic kidney disease: from haemoglobin variability to hyporesponsiveness.

Authors:  Angel L M de Francisco; Peter Stenvinkel; Sophie Vaulont
Journal:  NDT Plus       Date:  2009-01

9.  Serum prohepcidin levels are lower in patients with atrophic gastritis.

Authors:  Hyung-Keun Kim; Eun-Chul Jang; Ju-Ok Yeom; Sun-Young Kim; Hyunjung Cho; Sung Soo Kim; Hiun-Suk Chae; Young-Seok Cho
Journal:  Gastroenterol Res Pract       Date:  2013-02-28       Impact factor: 2.260

10.  Serum prohepcidin levels are potential prognostic markers in patients with multiple myeloma.

Authors:  Kouichi Haraguchi; Hirofumi Uto; Nobuhito Ohnou; Masahito Tokunaga; Mayumi Tokunaga; Atae Utsunomiya; Shuichi Hanada; Hirohito Tsubouchi
Journal:  Exp Ther Med       Date:  2012-08-18       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.